Skip to main content
. Author manuscript; available in PMC: 2020 May 6.
Published in final edited form as: Mol Pharm. 2019 Mar 28;16(5):1881–1889. doi: 10.1021/acs.molpharmaceut.8b01246

Figure 4. Antioxidant and epigenetic gene expression changes as described by indirect response model.

Figure 4

Phase II anti-oxidant and Epigenetic gene expression, including NRF2, HO-1, NQO1, and HDACs (1, 2, 3, 4) as described by the designated IDR model. The open circles represent the mean of the observed data in rat leukocytes, and the black lines represent the model prediction.